ERBB2 and lung adenocarcinoma: Moreover, with NGS analysis, they found HER2 point mutations in 38% of canine lung adenocarcinomas, and 93% of these HER2 mutations were hotspot V659E transmembrane domain (TMD) mutations, comparable to activating mutations at this same site in human cancer.